id: NEW:community_pharmacy_based_ioat_access_to_illicit_drug_use_past_month
name: Community Pharmacy-Based Injectable Opioid Agonist Treatment Access â†’ Illicit Drug Use Past Month
from_node:
  node_id: NEW:community_pharmacy_based_ioat_access
  node_name: Community Pharmacy-Based Injectable Opioid Agonist Treatment Access
to_node:
  node_id: illicit_drug_use_past_month
  node_name: Illicit Drug Use Past Month
direction: negative
category: healthcare_access
mechanism_pathway:
- 'Step 1: Community pharmacy-based model expands geographic and temporal access to injectable opioid
  agonist treatment (iOAT)'
- 'Step 2: Flexible dosing times and co-location with other pharmacy services reduces structural barriers
  to treatment engagement'
- 'Step 3: Regular supervised injection of prescribed opioids satisfies opioid dependence without requiring
  illicit drug acquisition'
- 'Step 4: Participants report 76% reduction in illicit opioid use and 45% reduction in other illicit
  substance use'
evidence:
  quality_rating: C
  n_studies: 1
  primary_citation: 'Tamara Mihic et al. 2025. "Community Pharmacy-Based Injectable Opioid Agonist Treatment:
    Findings From a Canadian Pilot Program.." https://doi.org/10.1111/dar.70062'
  supporting_citations:
  - Additional citations require full-text access - this abstract references oral OAT as comparator but
    does not cite specific studies
  doi: 10.1111/dar.70062
  citation_verified: true
last_updated: '2025-12-06'
version: '2.0'
description: Community pharmacy-based injectable opioid agonist treatment provides a novel, lower-barrier
  model for delivering evidence-based OUD treatment, resulting in substantial self-reported reductions
  in illicit opioid use among individuals who inject opioids and have not responded to oral treatment
  options.
quantitative_effects:
  effect_size:
    value: 76.0
    type: percentage_change
  sample_size: 51
spatial_variation:
  varies_by_geography: true
  variation_notes: Pilot program conducted specifically in Vancouver, Canada; generalizability to other
    geographic contexts requires further study
moderators:
- name: prior_oral_oat_non_response
  direction: strengthens
  strength: strong
  description: Program specifically targets individuals who have not responded to or do not prefer oral
    OAT, suggesting greater benefit for treatment-resistant populations
- name: overdose_history
  direction: strengthens
  strength: moderate
  description: Most participants had multiple previous overdoses, indicating high-risk population with
    greater potential for harm reduction benefit
structural_competency:
  equity_implications: This mechanism addresses structural barriers to OUD treatment including limited
    treatment availability, rigid dosing schedules, and fragmented healthcare services. By embedding iOAT
    in community pharmacies, the model reduces geographic and temporal access barriers that disproportionately
    affect marginalized populations. The approach avoids individual blame by recognizing that treatment
    non-response to oral OAT reflects medication-patient mismatch rather than personal failure.
llm_metadata:
  extracted_by: claude-opus-4-5-20251101
  extraction_date: '2025-12-06T21:12:36.809074'
  extraction_confidence: medium
  prompt_version: 2.1-canonical-validated
